NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
ImmunoGenesis
Alliance for Clinical Trials in Oncology
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals
Maastricht Radiation Oncology
Threshold Pharmaceuticals